Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 94
  • 357
  • 158
  • 13
  • 16
  • 328
  • 354
  • 3

Found 357 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
In the last decade, both the incidence and the survival of acute leukemia has been increasing. Therefore, detection of associated illnesses is important. We have recently observed that patients with acute leukemia treated with anthracyclines develop a high rate of symptomatic heart failure. To avoid this life-threatening illness, early detection …
 Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
18 years - 99 years
All genders
Phase 3
Interventional
This trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug …
 UPCC 24420: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)
18 years - 99 years
All genders
Phase 2
This study tests the safety and effectiveness of the combination of ublituximab, umbralisib, and venetoclax. Patients with Chronic Lymphocytic Leukemia (CLL) will be invited to participate in this trial.
 A Phase III  Randomized  Double-Blind  Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Sqamous Cell Carcinoma
99 years or below
All genders
The purpose of this study is to compare the effects of atezolizumab plus tiragolumab versus atezolizumab plus placebo or double placebo on subjects with esophageal cancer who have had at least 2 cycles of chemoradiotherapy without progression of their disease. Subjects with unresectable, locally advanced esophageal cancer will receive either …
 Penn Dermatology BioBank
99 years or below
All genders
The purpose of this study is to obtain consent to biobank skin specimens for future research studies. Skin growths, skin cancer, autoimmune or inflammatory skin diseases, and normal skin may be banked. Eligible patients include those who are seen at the University of Pennsylvania Health System clinical practices. For patients …
99 years or below
All genders
Phase 1
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose. ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not …
99 years or below
All genders
Phase 1
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: - To identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and - To assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy. …
99 years or below
All genders
Phase 1
Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints)
99 years or below
All genders
The primary objective of the study is to evaluate the safety and effectiveness of the NEUWAVETM FLEX MC Microwave Ablation System and Accessories used in transbronchial ablation procedures for adult subjects with oligometastatic tumors ( 2cm) in the lung. Technique Efficacy: Ablation of the target tumor(s) with the ablation zone …
99 years or below
All genders
Phase 2
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
21 - 30 of 357